Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis

Journal of Cardiovascular Pharmacology
Li Yue-ChunYang Zhan-Qiu

Abstract

Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis. However, the antioxidative effects of carvedilol have not been investigated in the setting of acute viral myocarditis. Therefore, this study investigated whether carvedilol protects against viral myocarditis primarily by its antioxidant and/or antiinflammatory properties. In a coxsackievirus B3 murine myocarditis model (Balb/c), effects of carvedilol and metoprolol on myocardial histopathological changes, cytokine levels, virus titers, malondialdehyde (MDA), and superoxide dismutase (SOD) contents were studied. Carvedilol markedly attenuated myocardial lesions and increased interferon-gamma and interleukin-12 production (cytokines) on day 7 with concomitant reduction of myocardial virus replication. In addition, only carvedilol decreased the content of MDA and increased the content of SOD on day 14. Metoprolol as well as bunazosin (a higly selective alpha1-adrenergic blocking agent) had no significant effects in this model. The results indicate that the superior protection of carvedilol in this model is probably the result of its antioxidative effects a...Continue Reading

References

Aug 1, 1988·Journal of the American College of Cardiology·S RezkallaR Khatib
Jan 1, 1983·Advances in Experimental Medicine and Biology·P K SingalN S Dhalla
Jun 1, 1993·Circulation·W G Guntheroth
Mar 17, 1997·Biochemical and Biophysical Research Communications·M VioraW Malorni
Jun 1, 1997·Journal of Neuroimmunology·C E Andrade-Mena
Sep 18, 1997·The Journal of Clinical Investigation·P Panina-BordignonF Sinigaglia
Sep 23, 1997·Journal of Molecular and Cellular Cardiology·T ShioiS Sasayama
May 20, 1999·Annual Review of Pharmacology and Toxicology·T P DaltonA Puga
Aug 18, 2000·The American Journal of Cardiology·C H MagsinoP Dandona
Aug 4, 2001·The New England Journal of Medicine·I W SeongE S Jeon
Sep 11, 2001·Journal of Molecular and Cellular Cardiology·T TanakaM Kurabayashi
Dec 20, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Zuyi YuanChiharu Kishimoto
May 18, 2004·The American Journal of Cardiology·Brian Dulin, William T Abraham
Oct 31, 2006·American Heart Journal·Richard Shannon, Mohammad Chaudhry

❮ Previous
Next ❯

Citations

Oct 30, 2010·Journal of Virological Methods·Jason L CanteraMarylynn V Yates
Oct 29, 2010·Journal of Medical Virology·Brigitte GlückPeter Wutzler
Sep 28, 2013·Archives of Cardiovascular Diseases·François RoubilleJean-Claude Tardif
Aug 22, 2009·Biochemical and Biophysical Research Communications·Wang HuaQi Chen
Nov 26, 2009·The Journal of International Medical Research·X F ZhuangNing Ling Sun
Nov 2, 2019·Basic Research in Cardiology·Joshua A SilverblattDaniel I Bromage

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.